Adding menopausal hormone therapy (MHT) to semaglutide was associated with significantly greater and sustained weight loss among women over 45, according to a study presented at The Menopause Society’s 2026 Annual Conference and reported by Medical News Today. The analysis, led by Regina Castaneda, MD, of Mayo Clinic Florida, drew on real-world health data for about 2,400 women taking semaglutide or tirzepatide, and has not yet undergone peer review.
For the peptide therapy and research peptide industry, the finding is a signal rather than a verdict: it suggests that the clinical conversation around GLP-1 peptides is moving toward combination protocols and patient stratification — by age, hormonal status and comorbidity — rather than a single-molecule race. Clinics, telehealth operators and compounding supply chains that already handle semaglutide and tirzepatide may face new questions from patients about adjunct hormone therapy, even though the evidence remains preliminary and correlational.
What the menopause and GLP-1 study actually found
Menopause typically occurs between the ages of 45 and 55, and researchers estimate that 60%–70% of women gain weight during menopause. Current options for menopausal weight gain include MHT, lifestyle changes and prescription GLP-1 receptor agonists, according to the report.
The Mayo Clinic Florida team analyzed health data for about 2,400 women over age 45 who were taking semaglutide (the active ingredient in Ozempic and Wegovy) or tirzepatide (the active ingredient in Zepbound and Mounjaro). Some participants were using MHT and others were not. In the semaglutide group, MHT use was linked to significantly greater and sustained weight loss. In the tirzepatide group, participants on MHT initially showed greater weight loss, but the end results did not reach statistical significance.
The report does not disclose effect sizes, confidence intervals or details of confounder adjustment, and the study has not been peer reviewed. Those omissions matter for anyone tempted to read the headline as a dosing rule.
Key numbers at a glance
| Item | Figure reported | Evidence status |
|---|---|---|
| Typical age range for menopause | 45–55 years | Background, reported |
| Share of women estimated to gain weight during menopause | 60%–70% | Attributed to researchers, not specified |
| Women in the analyzed dataset | About 2,400, over age 45 | Reported study detail |
| Semaglutide plus MHT outcome | Significantly greater and sustained weight loss | Association; effect size not reported |
| Tirzepatide plus MHT outcome | Initial greater loss; not statistically significant at end | Null result; question left open |
| Peer review status | Not yet peer reviewed | Conference presentation |
Why the finding matters for peptide therapy
Semaglutide and tirzepatide are peptides, and both sit at the center of the current metabolic-medicine market. Semaglutide acts on the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors — a mechanistic difference that Castaneda offered as one possible explanation for the divergent results. She also raised a “ceiling effect”: tirzepatide produces substantially greater weight loss on its own, leaving less room for hormone therapy to add measurable benefit.
Preclinical studies suggest estrogen may amplify GLP-1’s appetite-suppressing effects via GLP-1 receptor signaling, according to Castaneda. That is animal and laboratory evidence, not a demonstrated human mechanism, and it should not be presented to patients as an established pathway.
Castaneda described the results as “hypothesis-generating” and said they do not mean hormone therapy should be prescribed solely to improve weight-loss outcomes, because weight management is not a clinical indication for MHT. She also said the tirzepatide finding does not mean MHT has no effect in women taking that drug, and called for larger studies with longer follow-up and better control of confounders.
Independent commentators who were not involved in the study framed menopausal weight as a broader clinical problem. Sheryl Ross, MD, a board-certified ob-gyn at Providence Saint John’s Health Center in Santa Monica, California, noted that weight gain — particularly “meno” belly weight gain — increases the risk of diabetes and heart disease, and said GLP-1 use in menopause has risen. Prudence Hall, MD, an ob-gyn in private practice in Santa Monica, argued that hormone replacement therapy addresses systemic drivers such as estradiol depletion, adrenal dysregulation and cortisol, testosterone decline and thyroid slowing. Hall’s assertion that even subclinical drops in thyroid function can drive 20 to 25 pounds of weight gain is a single expert opinion and is not independently supported in the report.
Research and market context: stratification, not substitution
The study does not compare MHT with GLP-1 therapy, and it does not test a combination product. It observes an association inside real-world data, which means confounding by indication is a live possibility: women who take MHT may differ from those who do not in symptom burden, health behaviors, access to care or socioeconomic status. Nothing in the report establishes that MHT causally amplifies semaglutide’s effect.
For the research peptide sector, the more durable takeaway is methodological. As GLP-1 peptides move deeper into midlife women’s health, trial and real-world datasets will increasingly need to capture hormonal status, menopausal symptom burden and concurrent hormone use as structured variables rather than free-text notes. That is a data-quality question before it is a marketing question.
For clinics and telehealth platforms, the practical implication is conversational: patients will ask whether adding hormone therapy will improve their response to a GLP-1 peptide. The defensible answer, based on this evidence, is that an association has been reported in a non-peer-reviewed conference analysis, that causality is unproven, and that MHT prescribing decisions should rest on approved indications and medical supervision — not on weight-loss goals alone.
Supply-side readers should also note what the study does not say. It provides no information on dose, formulation, device, vial or cartridge presentation, storage conditions or sourcing. Any claim that a particular presentation of semaglutide or tirzepatide performs differently in menopausal women is not supported by this dataset. Peptidescm as a provider in the industry domain maintains that product-level quality documentation — identity, purity method, batch traceability — must be evaluated separately from clinical association studies of this kind.
What comes next
Castaneda’s stated next step is larger studies with longer follow-up and better confounder control. Until such work is published and peer reviewed, the semaglutide–MHT association should be treated as a hypothesis worth testing, and the tirzepatide question as genuinely open.
Readers tracking this space should watch three things: whether the conference analysis advances to a peer-reviewed journal with effect sizes and adjusted models; whether subsequent work separates the effect of symptom relief and improved quality of life from a direct hormonal-metabolic interaction; and whether real-world datasets begin recording menopausal hormone status systematically. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
For readers who want to follow how such clinical signals translate into supply-chain and sourcing decisions, PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
Frequently asked questions
Does hormone therapy boost semaglutide weight loss?
A non-peer-reviewed analysis of about 2,400 women over 45 found that MHT use was associated with significantly greater and sustained weight loss among semaglutide users. The study is correlational, reports no effect size, and its lead author called the results hypothesis-generating.
Did the same effect appear with tirzepatide?
Participants taking tirzepatide initially showed greater weight loss with MHT, but the end results did not reach statistical significance. The lead author said this does not mean MHT has no effect in tirzepatide users.
Should MHT be prescribed to improve weight loss?
No. Weight management is not a clinical indication for menopausal hormone therapy, and the lead author explicitly said the findings do not support prescribing MHT solely for weight-loss outcomes.
Is this evidence that estrogen amplifies GLP-1 in humans?
Not yet. The proposed mechanism rests on preclinical studies suggesting estrogen may amplify GLP-1 receptor signaling; human relevance has not been established in this study.
Comments